Foresite Capital Management VI LLC Invests $8.46 Million in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)

Foresite Capital Management VI LLC acquired a new position in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 1,581,233 shares of the company's stock, valued at approximately $8,460,000. Corvus Pharmaceuticals comprises approximately 3.8% of Foresite Capital Management VI LLC's holdings, making the stock its 9th biggest position. Foresite Capital Management VI LLC owned about 2.46% of Corvus Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also modified their holdings of the company. Virtus ETF Advisers LLC bought a new position in Corvus Pharmaceuticals in the 4th quarter worth $47,000. Alpine Global Management LLC bought a new position in shares of Corvus Pharmaceuticals in the fourth quarter worth about $62,000. Tower Research Capital LLC TRC acquired a new position in shares of Corvus Pharmaceuticals during the 4th quarter worth about $74,000. Vivo Capital LLC boosted its stake in Corvus Pharmaceuticals by 49.2% during the 4th quarter. Vivo Capital LLC now owns 2,234,566 shares of the company's stock valued at $11,955,000 after purchasing an additional 737,298 shares during the period. Finally, Dimensional Fund Advisors LP boosted its stake in Corvus Pharmaceuticals by 91.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 22,793 shares of the company's stock valued at $122,000 after purchasing an additional 10,869 shares during the period. 46.64% of the stock is owned by institutional investors.

Corvus Pharmaceuticals Stock Up 2.8 %

Corvus Pharmaceuticals stock traded up $0.10 during trading hours on Friday, hitting $3.62. The stock had a trading volume of 1,128,121 shares, compared to its average volume of 652,771. Corvus Pharmaceuticals, Inc. has a fifty-two week low of $1.43 and a fifty-two week high of $10.00. The company has a market cap of $246.77 million, a PE ratio of -3.89 and a beta of 0.67. The company has a 50-day moving average of $3.66 and a two-hundred day moving average of $5.62.

Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) last issued its earnings results on Tuesday, March 25th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.06). As a group, analysts forecast that Corvus Pharmaceuticals, Inc. will post -0.63 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

CRVS has been the subject of a number of research analyst reports. Oppenheimer reiterated an "outperform" rating and set a $15.00 price target (up from $14.00) on shares of Corvus Pharmaceuticals in a report on Wednesday, March 26th. HC Wainwright reiterated a "buy" rating and set a $11.00 target price on shares of Corvus Pharmaceuticals in a research note on Wednesday, March 26th. One analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Corvus Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus price target of $15.67.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.